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METHODS
Statins are cholesterol lowering drugs that have shown a
profound effect on human health by reducing
cardiovascular disease. However, two recent
publications in the Journal of Infectious Diseases showed
that statin use had a negative impact on the influenza
vaccine response in elderly individuals [1, 2]. We
propose to evaluate the immune response following
vaccination in mice undergoing statin treatment. An initial
study will determine the therapeutic window for statin
treatment of mice fed a lipid-enriched diet. From the
literature this window is expected to be between 21-28
days. That therapeutic window will be used for evaluation
of the immune response following vaccination with an
inactivated influenza vaccine. After treating the mice with
statins for the optimum time to see an effect, we will
vaccinate mice and evaluate the immune response to
vaccination. Current lab activities are focused on
developing assays to determine cholesterol, trigyceride,
and HDL-cholesterol levels in mice.
In a recent review of the literature for appropriate animal
models to study the efficacy of statins, Pecoraro, et al
stated that “Given the complexity of cardiovascular
diseases and its multifactorial nature, it is unlikely that a
single model will perfectly represent human physiology…”
[3]. The main difficulty with the use of mice for the study
of statins is that they lack the plasma cholestereryl ester
transfer protein that facilitates the transport of cholesteryl
esters and triglycerides between lipoproteins. Therefore,
mice are not the best model of atherogenesis in humans.
However, these authors also suggest the use of Apo E-/-
transgenic mice in studies to model severe dyslipidemia
[3]. When fed a lipid-enriched diet, the total cholesterol in
Apo E-/- knockout mice can reach five times the level in
wild-type C57BL/6J mice, and statins have been shown to
significantly reduce the total cholesterol [4]. In addition,
studies in Apo E-/- mice have shown the anti-
atherosclerotic effect of statins through an anti-
inflammatory mechanism on heart vessels in addition to
their cholesterol-lowering activity [4,5].
We propose to evaluate the immune response following
vaccination in Apo E-/- transgenic mice undergoing statin
treatment. An initial study will determine the therapeutic
window for statin treatment of transgenic mice fed a lipid-
enriched diet. From the literature this window is expected
to be from 21-28 days. That therapeutic window will be
used for evaluation of the immune response following
vaccination with an inactivated influenza vaccine. After
treating the Apo E-/- transgenic mice with statin for the
optimum time to see an effect, we will vaccinate mice and
evaluate the immune response to vaccination. A group of
wild-type mice will also be evaluated in parallel to
determine if the gene knockout is required to show the
effect on the immune response, or if simply the duration of
treatment will produce the effect.
Figure 3: Cholesterol and Triglyceride Reagent Sets. Used to 
quantitatively determine cholesterol and triglyceride amounts 
in serum and plasma.
Cholesterol assay
No./
Cage
Grou
p No. Treatment
Dose 
(mg/kg/day) Mouse
Observations / 
Testing
10 1 Simvasatin 10
Apo E-/-
Blood collected 
prior to treatment, 
then 2x per week 
for cholesterol 
determination
10 2 Simvasatin 30
10 3 Simvasatin 100
10 4 Placebo NA
10 5 Simvasatin 10
Wild-
type
10 6 Simvasatin 30
10 7 Simvasatin 100
10 8 Placebo NA
Study 1: Determination of therapeutic treatment time:
No./
Cage
Group 
No. Vaccine Statin
Dose 
(mg/kg/day) Mouse
Observations / 
Testing
20 1 IIV* Simvasatin TBD
Apo E-/-
Blood collected 
prior to 
treatment, then 
2x per week for 
cholesterol 
determination.
Blood collected 
pre and post 
vaccination for 
serological 
evaluation.
20 2 IIV Placebo NA
3 3 Controls observed for normal weight gain
20 4 IIV Simvasatin TBD
Wild-type
20 5 IIV Placebo NA
3 6 Controls observed for normal weight gain
Study 2: Evaluation of immune response following vaccination:
IIV* = inactivated influenza vaccine 
Pipette 1.0 ml of reagent, pre-warm, then add .01 mL (10ul) of the
sample into each tube. Incubate at 37°C for five minutes. Insert
into zero spectrophotometer with reagent blank at 520nm, and
record absorbances of all test tubes.
Triglyceride assay
Pipette 1.0 ml of reagent into each cuvette. Place all tubes in
incubator and bring reagent up to 37°C. Pipette 0.01 ml (10ul) of
sample into respective tubes. Incubate all tubes for five minutes at
37°C. Zero spectrophotometer at 540nm with reagent blank, and
record absorbances of all test tubes.
This study has a high potential for human benefit. Dr. Tarbet
hopes to ultimately determine whether statin use by humans can
be temporarily discontinued in order to allow for a greater
response to the influenza vaccine. It is assumed that this window
would be only a few weeks or less in duration. According to
guidelines set by the AHA (American Heart Association), the
number of U.S. adults receiving or eligible for statin therapy is
approximately 56.0 million, with 87.4% of men and 53.6% of
women between the ages of 60-75 eligible for the drug [6]. The
results of this study could help millions to more effectively receive
an important vaccination.
